Answers are grounded in this paper and cite their sources.
This study is the first to demonstrate safety of SVF infusion in humans with serious pulmonary disease. Specifically, the use of intravenous infusion as a route to achieve pulmonary cellular targeting did not lead to clinical pulmonary compromise. The intravenous administration of SVF should be further explored as a potentially feasible and safe method for delivery leading to possible therapeutic benefit.
No takes yet. Share an insight, caveat, or question.
Comella et al. (2017) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: